Project Grant R56HL167896
Award Date
9/23/23
Completion Date
8/31/24
Dollars Obligated
$808K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Milwaukee, WI 53226, USA
Similar Awards
This Federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is supporting research to leverage large-scale biobanks to discover and define rare genetic variant effects on hypertrophic cardiomyopathy (HCM). The $767,579 award to Vanderbilt University Medical Center (VUMC) aims to address key knowledge gaps by: 1) defining the contribution and phenotypic manifestations of established HCM disease...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $782,672 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Brigham & Women's Hospital. The grant funding will support research to identify previously unrecognized genetic causes of congenital heart disease (CHD). The project aims to assess the contributions of non-coding and rare coding variants to unexplained CHD cases, using a combination of cell-based functional assays, single-nucleus RNA...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute of MIT and Harvard to investigate the genetic basis and underlying mechanisms of heart failure (HF). The project aims to leverage high-throughput functional genomic approaches, including cell painting and Perturb-seq, to systematically assess the impact of HF-associated genetic risk loci on...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will develop, validate, and determine the clinical utility of a precision genetic testing approach guided by machine learning algorithms. The $756,895 award to Duke University, with sub-awards to Mayo Clinic and the Medical University of South Carolina, aims to enhance the diagnosis of two monogenic cardiovascular disorders: hypertrophic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $624,142 to the University of Colorado-Denver to conduct an integrated genomic and transcriptomic investigation of human heart failure mechanisms. The project aims to leverage whole-genome and whole-transcriptome data from a unique dataset of ~750 paired DNA/RNA sequenced human heart samples to: 1) validate which heart failure GWAS...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $1,413,971 Project Grant to the University of Pittsburgh to study the role of the MDM2-HIF signaling axis in regulating pathological left ventricular remodeling. The research aims to define how this signaling pathway impacts myocardial microvasculature, metabolism, and remodeling in both genetic and pressure overload models of left ventricular hypertrophy. The...
This federal Project Grant award, ID R01HL175964, is supported by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $719,462 grant is provided to Baylor College of Medicine to develop a high-throughput variant interpretation approach for the MYH7 gene, which is broadly applicable to other cardiomyopathy and genetic diseases. The project aims to use single-cell RNA sequencing and machine learning to identify gene...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Research Institute at Nationwide Children's Hospital in Columbus, Ohio. The $711,039 award, which runs from March 6, 2025 to December 31, 2029, will support research to determine the role of cardiac m6A methyltransferases in the pathogenesis of fetal dilated cardiomyopathy. The project aims to use mouse genetics, biochemistry, molecular biology, RNA biology,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $267,310 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania. The grant, effective June 29, 2024 through December 31, 2026, will fund research to investigate ancestry-specific genetic variations associated with heart, lung, blood, and sleep (HLBS) disorders. The research aims to...
This $756,039 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate how non-coding genetic variants affect the severity of cardiomyopathies caused by haploinsufficiency. The grantee, the Regents of the University of Michigan, will utilize human induced pluripotent stem cell-derived cardiomyocytes and mouse models to quantify the gene expression impacts of single...